JBCHEPHARM JB Chemicals & Pharmaceuticals Q4 FY25 results (Jan–Mar 2025) and concall
J B Chemicals delivered a strong Q4 FY25, characterized by consistent outperformance in the domestic chronic segment and a recovery in the CDMO business. The company is successfully transitioning its international mix toward higher-margin private markets and CDMO projects. Management's decision to raise EBITDA margin guidance to 27-29% reflects high confidence in operating leverage and the upcoming margin-accretive transition of the ophthalmology portfolio.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|
| Revenue | 952 | 956 | 914 | 901 |
| EBITDA | 273 | 268 | 245 | 231 |
| Net profit | 173 | 173 | 156 | 150 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
